Please login to the form below

Not currently logged in
Email:
Password:

SGLT2 inhibitors

This page shows the latest SGLT2 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Merck, Bayer flesh out vericiguat heart failure data at ACC

Merck, Bayer flesh out vericiguat heart failure data at ACC

Some outstanding questions include where vericiguat lies in relation to the SGLT2 inhibitors such as Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga/Forxiga (dapagliflozin), which are also ... Here too the SGLT2

Latest news

  • FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

    There are around 40, 000 new type 1 diabetics diagnosed in the US every year, and at the moment no SGLT2 inhibitors have been approved for adjunctive use with insulin. ... It also turned down Lexicon Pharma and Sanofi’s SGLT2 inhibitor Zynquista

  • Trial of Amgen, Servier’s heart failure drug clears interim check Trial of Amgen, Servier’s heart failure drug clears interim check

    Other drugs in the SGLT2 class – including Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) – are also being tested in heart failure indications. ... GlobalData expects the SGLT2 inhibitors in particular to stimulate strong growth in

  • Bayer, Merck’s high-risk heart failure drug comes good in phase 3 Bayer, Merck’s high-risk heart failure drug comes good in phase 3

    Another question for vericiguat is how it will stack up against SGLT2 inhibitors such as Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin). ... added. At the moment there are no studies involving

  • FDA advisors say no to empagliflozin in type 1 diabetes FDA advisors say no to empagliflozin in type 1 diabetes

    The panel said that the data on a 2.5mg dose of the SGLT2 inhibitor – already approved for type 2 diabetes at a higher dose under the trade name Jardiance – suggested ... SGLT2 inhibitors could provide an oral alternative, if approved.

  • Sanofi exits Zynquista alliance with Lexicon Sanofi exits Zynquista alliance with Lexicon

    The drug is a dual inhibitor of SGLT1 and SGLT2 and was thought to work by reducing glucose absorption in the gastrointestinal tract and glucose reabsorption by the kidneys, as well ... Sanofi/Lexicon had hoped that the dual targeting may provide added

More from news
Approximately 5 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J&J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    the way SGLT2 inhibitors work by reducing the amount of glucose absorbed in the kidney and passing it out through urine. ... Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including

  • Pharma deals during April 2013 Pharma deals during April 2013

    The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... SGLT2 inhibitors block the reabsorption of glucose by the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics